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Genomic Contraindications
for Heart Transplantation
Danton S. Char, MD,a,b,c Gabriel Lázaro-Muñoz, PhD, JD, MBE,d,e Aliessa Barnes, MD,f
David Magnus, PhD,b Michael J. Deem, PhD,g John D. Lantos, MDh

Genome sequencing raises new ethical challenges. Decoding the genome
produces new forms of diagnostic and prognostic information; however, the
information is often difficult to interpret. The connection between most
genetic variants and their phenotypic manifestations is not understood.
This scenario is particularly true for disorders that are not associated with
an autosomal genetic variant. The analytic uncertainty is compounded
by moral uncertainty about how, exactly, the results of genomic testing
should influence clinical decisions. In this Ethics Rounds, we present a
case in which genomic findings seemed to play a role in deciding whether a
patient was to be listed as a transplant candidate. We then asked experts in
bioethics and cardiology to discuss the implications of such decisions.

Genome sequencing raises new
ethical challenges. Decoding the
genome produces new forms of
diagnostic and prognostic information;
however, the information is often
difficult to interpret. The connection
between most genetic variants and
their phenotypic manifestations is
not understood. This scenario is
particularly true for disorders that
are not associated with an autosomal
genetic variant. The analytic
uncertainty is compounded by moral
uncertainty about how, exactly, the
results of genomic testing should
influence clinical decisions. In this
Ethics Rounds, we present a case
in which genomic findings seemed
to play a role in deciding whether a
patient was to be listed as a transplant
candidate. We then asked experts in
bioethics and cardiology to discuss the
implications of such decisions.

THE CASE
A 12-year-old boy with Tetralogy of
Fallot and pulmonary atresia with
multiple aortopulmonary collaterals
is admitted with worsening heart

failure and is being considered for
heart or combined heart and lung
transplantation. During extracorporeal
membrane oxygenation (ECMO) after
a previous heart surgery, the patient
experienced a thrombotic event
resulting in a left middle cerebral
artery stroke, leaving him with rightsided hemiparesis and dysarthria. He
has had several venous thromboses,
despite normal results on all routine
laboratory tests of clotting function.
The patient also has developmental
delay and hypothyroidism.
Whole genome sequencing (WGS)
is performed both to potentially
provide a unifying diagnosis for the
cardiac defects, hypothyroidism, and
developmental delay, as well as (given
the complexity of performing heart
transplantation in a child who has
had multiple prior cardiac surgeries)
to screen for genetic variants that
might explain the patient’s recurrent
thrombotic events. Analysis of
WGS confirms that the patient has
DiGeorge syndrome (DGS), a 22q11
deletion, but also reveals that he has
a particular variant of 22qDS highly
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associated with schizophrenia and
multiple variants in several other
genes associated with schizophrenia,
including in his type 2 dopaminergic
receptors; these variants make
it very likely that he will develop
schizophrenia and that the disease
may be severe. The patient was
adopted, and thus a confirmatory
family history is not available.
Given the psychosocial challenges
associated with management of a
transplanted organ in adolescents,
the challenges to self-care posed
by the patient’s already-present
developmental delay and stroke, the
scarcity of available pediatric donor
organs, and with the WGS findings,
the heart failure team decides that
they will not go forward with listing
the patient for a transplant. Without
the prospect of a future transplant,
the team feels the patient would be
a poor candidate for a ventricular
assist device.
The family objects to the team’s
decision and states that had they
known the WGS results could lead
to taking away options, they would
never have given permission for the
test. How should the team respond?
Should they have disclosed the
possibility that the findings would
be used as a basis to deny treatment
before testing?”

Drs Char and Magnus Comment
WGS in pediatrics has the potential
to create psychosocial burdens on
children and their families.1 This
clinical case highlights one of the
most severe potential harms: a
child may be denied a life-saving
therapeutic option (in this case,
a transplant organ) based on the
results of WGS. This concern is a
real possibility. Scarce resources
in pediatric acute care (eg,
transplantation, extracorporeal
oxygenation, complex surgical
interventions) are already rationed
by clinicians based on the results
of the genetic testing currently
in clinical use.2–5 WGS has the

potential to expand the number of
genetic findings that may be used
as justification for rationing scarce
resources.6,7 This potential use of
WGS results is not appropriate. The
technology is new and still hard
to interpret, the spectrum of false
results is still unclear, most WGS
findings have not been rigorously
studied, and the prognoses stemming
from these WGS findings are not well
validated.
For genetic diagnoses that already
have rigorously studied prognoses,
WGS findings (particularly if
corroborated with other, established
tests) may be used to make a
prognosis in an individual child and,
consequently, potentially limit access
to a scarce resource. The pressure to
best triage scarce resources is strong.
Acute care resources, particularly
transplant programs, need to steward
their precious resources toward the
children these resources will most
benefit. Data that provide guidance
for these difficult triage choices
are invaluable to these acute care
clinicians.
However, the track record for
efforts at such stewardship is mixed.
Despite growing evidence that
developmentally delayed patients
have survival rates equivalent
to other patients who receive
transplants,8,9 transplant programs
often (although inconsistently) use
this delay as a basis for denying
transplantation. Forty-four percent of
US pediatric heart, liver, and kidney
transplantation programs report that
they “usually” or “always” consider
the developmental delay in their
decision process.5 In addition, lung
and heart transplantation physicians
have explicitly stated that they would
also withhold transplantation in
children with genetic defects.4
Currently, clinicians ration other
scarce resources in children based
on genetic findings associated with
developmental delay, cognitive
impairment, and the potential for a
poorer prognosis. For example, 91%

of ECMO center directors stated they
would not offer ECMO to a child with
trisomy 13, and 90% would never
offer ECMO to a child with trisomy
18; 32% would not offer ECMO to a
child with trisomy 21 who otherwise
met criteria.2 For high-risk surgeries,
such as with the complex congenital
cardiac disease hypoplastic left
heart syndrome, clinicians refuse
to operate on some children with
trisomies.3
As WGS becomes better studied,
validated, and implemented, it will
allow individualized drug therapies
and guide early interventions.
However, the results of WGS testing
may also be used as justification
for declaring futility of care and for
guiding scarce resources to another
child.
In the present case, the secondary
WGS findings became part of the
deliberations by the heart failure
team in choosing whether to list the
patient for potential transplantation.
This action is not surprising. As
stewards of scarce resources,
pediatric transplant programs steer
resources to those who will best
benefit from them. Such programs
also have concerns about graft
survival and how poor posttransplant
outcomes might reflect on, and
impact the survival of, the program
itself.4
However, there are problems in
using WGS findings in this way.8
The suggestion of the potential for a
particular disease or syndrome based
on WGS results may not be reliable
enough to play such a critical role in
life-and-death decisions. This concept
is especially true for predictive
tests (ie, those which are not used
to diagnose disease in a setting of
current clinical manifestations but,
instead, to predict future onset
of disease). Technical concerns
regarding understanding all of the
potential WGS testing pipeline errors
are still being worked out.8
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Even if the WGS findings were
wholly accurate and the subsequent
manifestation of disease stemming
from the findings is likely, concerns
would remain. What sort of future
diseases ought to preclude lifeprolonging treatment today? It is
not obvious that an increased risk of
later-onset schizophrenia should be a
contraindication to transplant.
Because WGS findings may be used
to limit care, it is reasonable to
require (at the present time) that all
such testing should necessitate a full
and explicit informed consent that
includes discussion of the ways in
which such tests have the potential to
be used as part of the triage process
and may inform what clinical options
are available. Private WGS testing
of children (eg, through direct-toconsumer platforms) should be
similarly explicit about the longer
term implications of the WGS results.
WGS results need to be rigorously
studied. Given the complexity of
these results, it is unlikely that the
bedside clinicians making acute
decisions, such as the team in this
case example, will be aware of how
to interpret all the limitations of
particular WGS findings. Additional
education and knowledge support
will be needed. In addition, as
WGS prognostic data emerge,
clinicians will need to explicitly
and transparently justify their
triage decisions surrounding scarce
resources to make sure they are
cognizant of when they are serving
as good stewards of these scarce
resources and to protect them from
acting in a prejudicial manner toward
those with cognitive or behavioral
disabilities. Most importantly, for at
least the present, clinicians will need
to convey the potential for limitations
on what care will be offered based
on WGS findings as part of the
informed consent process to families
considering WGS.

Dr Lázaro-Muñoz Comments
The American College of Medical
Genetics and Genomics recommends
that before ordering diagnostic WGS
for children, the child’s parents
or guardian should be informed
of the potential risks and benefits
and asked to provide consent.10 As
fiduciaries, clinicians have a duty to
disclose information that is material
to making an informed decision
regarding WGS and other types of
medical interventions.11 The fact
that the WGS results could be used
to deny access to a potentially lifesaving heart transplant can safely be
regarded as material information.
This foreseeable consequence of
WGS should have been disclosed
by the team before the testing was
conducted. The family’s assertion
that they would have never given
permission to the test had they
known the results could lead to
taking away options—although
stated in hindsight—further supports
the notion that this information is
material for informed consent.
One argument against this scenario
could be that the test results were
not anticipated. They should have
been, however. Given the child’s
clinical presentation (ie, congenital
heart disease, developmental delay,
hypothyroidism), it was anticipatable
that WGS could reveal 22qDS, a
variant that is known to be associated
with schizophrenia.12 Therefore, the
potential for an incidental finding
of increased risk for schizophrenia,
which would have implications for
the child’s psychosocial evaluation
as a transplant candidate, was
foreseeable. Because it was material
for decision-making, it should have
been communicated during the
consent process. At a bare minimum,
guidelines suggest that the team
should have disclosed the possibility
of incidental and secondary target
findings with WGS that might have
led to reconsideration of the child’s
eligibility for transplant.13,14

Failure to disclose all this
information restricted the family's
ability to decide what was in the
best interest of their child regarding
WGS. The surprise of learning that
the WGS results would be used to
deny medical options likely made the
family feel misinformed, and perhaps
deceived, by the clinical team. This
situation can negatively impact
the trust necessary for an effective
clinician–patient relationship.15
Disclosure oversights are likely
to occur when introducing novel
technologies in medical care.
However, there is a growing body
of literature that addresses how to
anticipate and manage many of the
issues regarding incidental findings
of WGS.16–18 As WGS becomes more
accessible and common in clinical
practice, clinicians must not only
stay abreast of data about the clinical
usefulness, technological capacities,
and limitations of WGS, but they
must also be prepared to address
the clinical ethics challenges and
potential harms that genomic testing
can generate.
Presumably, the WGS results
suggesting an increased risk for
schizophrenia played an important
role in the team’s decision not to
list the child for a transplant. The
other psychosocial challenges (eg,
difficulties of self-care because of
developmental delay and stroke,
patient near adolescence) were
already present before WGS.
However, these results should
be interpreted with caution. The
genetics of schizophrenia are
becoming clearer,19–21 but many
ambiguities and uncertainties
remain. For example, although earlier
reports estimated the penetrance
of schizophrenia in 22qDS to be
as high 55%,22 recent studies with
larger samples suggest it is as low as
12%.23 Thus, the clinical team should
reconsider the weight it gave to the
schizophrenia-associated variants
and consult with a medical geneticist
or genetic counselor before making
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a final decision about the child’s
candidacy for transplantation.
Moving forward, the team should
call for an ethics consult or identify
a team member that has rapport
with the family to help facilitate
communication. The team should
have a frank discussion with the
family to explain the difficult
patient-centered and public health
interests that must be balanced
when determining whether to list a
child as a transplant candidate and
why they felt they could not list this
child. As part of that discussion, the
team should clarify why they did
not disclose that WGS results could
be used to deny access to certain
medical options and ideally apologize
for this omission. In addition, the
team should advise the family about
alternatives, including the possibility
of other programs that may accept
the child as a transplant candidate.
Above all, they should remain
available to assist the parents in their
ongoing decisions about their child’s
health care.

transplant journey together.
Effective communication is critical.
Some of the key concepts in this
communication process include:
1. Transplant involves trading one
set of issues for a different set
of issues. Transplant is not a
cure. A transplant parent never
stops worrying what the next
day will bring due to the major
complications of rejection,
infection, and cancer. These issues
can occur on day 1 of transplant or
20 years later. A transplant patient
will be taking time-sensitive
medications for life. Patients will
have physician appointments,
laboratory tests, and studies
for the rest of their life. It is
imperative that the family fully
understands the importance and
complexity of adherence in the life
of a transplant patient.

Cardiac transplantation is typically
a last option. Usually, if a transplant
is not possible, the child will die.
Families think of transplant as the
one choice that will fulfill their hopes
for cure.

2. There must be a very thorough
evaluation before listing a patient
for transplant. We must help
families understand that the
evaluation is to be sure that the
procedure transplant and life
after transplant are going to be
successful. We must help families
to understand that the purpose
of the pretransplant evaluation
is to maximize the chance that
the procedure will be successful.
They should understand that, as
part of this evaluation, we will
do a number of tests that may
change our recommendations
about whether to recommend
a transplant. At times, there
are unique issues that cannot
be predicted but still serve as a
contraindication to transplant due
to their likely negative impact on
transplant outcomes.

A transplant physician and
team are charged with many
critical responsibilities. There
are misconceptions that must be
clarified, expectations that must be
realistic, and concepts that must
be understood before physicians,
patients, and families start the

3. The decision of whether a patient
will be listed is mandated by the
government to be a decision made
by a multidisciplinary group of
experts based on their opinion
of the likelihood of positive
outcomes. This conclusion is
a grave decision that must be

Dr Barnes Comments
Families hope and expect that data
will point to a clearly optimal choice
regarding the best decision for their
child. Physicians and families both
hope for a choice that will lead to the
child being well again. They want to
be able to look back on the nightmare
of life-threatening illness as a distant
memory.

critically discussed and cannot
be based on 1 person’s thoughts
or analysis. A group of experts
that represents all aspects of the
patient’s care discuss all findings
of the evaluation and decide if
any additional testing should be
conducted or if there is adequate
information to make a decision.
Any additional testing is to be sure
that any important information
is not missing that may make the
transplant a failure.
4. Being placed on the transplant
waiting list does not guarantee
that a child will get a heart
transplant. Families must
understand ahead of time that
listing for cardiac transplantation
is a dynamic situation. Even if
a patient is listed, the patient
will be evaluated regularly to
determine if he or she is still a
candidate who will likely have a
successful outcome. If there is any
change or additional information
is revealed, it may or may not
affect listing status, and the family
should be fully informed of this
possibility. This juncture is where
we explain the use of Status 7.
Status 7 on the transplant waiting
list indicates that the patient is
still on the list but will not receive
new organ offers. The transplant
team will use this status until
any new questions are fully
investigated and will not accept
a heart until they again know it
will be a success. Families also
need to understand that children
may get too sick before a heart
becomes available because it is
such a scarce resource. Death
while on the waiting list is always
a possibility, and families must be
prepared for this possibility.
All of these important aspects and
more must be discussed with the
family before starting the heart
transplant evaluation. Most centers
have a “transplant talk” that can
take anywhere from 45 minutes
to 3 hours. Most centers feel this
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talk is so important that there is a
signed consent to evaluation that the
parents must agree to before starting
the evaluation.
The question arises regarding
whether transplant teams can ever
achieve fully informed consent
from families related to transplant.
The families are often emotional
and traumatized, reeling from the
thought that their child needs a
transplant. Many times, as in this
case, this finding is just one more
piece of traumatic bad news in a
line of frightening information and
experiences for the child and the
family. We know that when parents
are that emotionally stressed, they do
not understand or retain information.
But what choice do we have?
It is the transplant team’s burden to
try to assess parents’ understanding,
work at ways to help them cope
with the stress, and help them
understand the information that
we are providing. One strategy to
address these concerns involves
having the psychosocial team assess
how the family learns best. In
addition, psychologists can evaluate
the level of emotional stress and
capacity, and other team members
may check understanding and fill
in any gaps that are found with
repeated conversations. The family
is given the written consent to read
later for better comprehension.
Most centers have a transplant book
for parents that includes abundant
information about transplant life and
the evaluation.
Although we try, it is impossible
to explain everything that may
be uncovered on a pretransplant
evaluation. Perhaps, in the present
case, the team did try to explain at
least the possibility of something
being found that would change their
thoughts regarding the patient being
a good candidate for transplantation.
Perhaps the family did not hear or
understand that information in their
emotional state.

In this situation, I believe that the
team should stress that the decision
to not list for transplantation was
not based solely on the WGS test
result but the combination of issues
that made the patient a high-risk
candidate. The family needs to
understand that the physicians
are not taking away an effective
treatment but are, instead, trying
to avoid the likelihood of an
unsuccessful transplant. To reinforce
this approach, they should offer to
send the patient’s data to another
center for a second opinion if the
family desires. In this case, I believe a
majority of centers would agree with
the final decision due to the many
serious medical issues.

of a proposed medical test or
treatment, their ability to make
informed medical decisions is
compromised. It is reasonable
for patients or their surrogates
to view denial of treatment as a
foreseeable, unwanted, and harmful
effect of WGS. This risk ought to
be disclosed and clarified when
patients or their surrogates consider
WGS. The team, then, had a duty to
disclose the possibility that WGS
findings would be the basis for the
denial of certain treatments. If that
information was not provided to
the parents, the consent process for
WGS was ethically problematic, and
their opposition to the decision is
warranted.

The bottom line is that transparent
and clear communication are
crucial from the beginning but are
sometimes thwarted by the stressful
and emotional state the family and
team function in every day. It is
impossible to prepare families for
everything, but being sure to cover
the critical concepts in a way families
can comprehend usually paves the
way to well-prepared families and
open lines of communication for hard
conversations.

The ethical problems in this case
do not stem solely from the consent
process. Although the team’s
reluctance to list the patient for
transplantation is understandable,
there are grounds for questioning
the strength of the reasons the team
offered to justify its decision. Let us
briefly consider each reason the team
offered.

Dr Deem Comments
This case highlights an important
ethical question associated with the
clinical application of WGS. Given
WGS’s potential to affect clinical
management in ways a patient or his
or her surrogates might regard as
harmful, do clinicians have a duty to
disclose that possibility during the
consent process for WGS?
On the basis of the medical team’s
stated aim in ordering WGS, as well
as the parents’ reaction to the team’s
decisions, we may reasonably infer
that the parents did not possess
adequate information about the
potential impact of WGS on their
child’s clinical management. When
patients or their surrogates hold
inadequate information about
the possible benefits and risks

Psychosocial Challenges
Tetralogy of Fallot typically requires
multiple surgeries beginning in
infancy. Given the co-presentation
of pulmonary atresia and
aortopulmonary collateral arteries
in this case, we may conclude
that the patient required staged
repairs.24 Moreover, 22q11.2
deletion syndrome is associated
with longer postoperative intensive
care.25 Having already faced the
psychosocial challenges of several
complex pediatric surgeries and
postoperative care, this particular
family is likely well acquainted with,
and well prepared to handle, the
challenges arising from pediatric
transplantation.

Challenges to Self-care
How the patient would manage
the challenges of self-care after
transplantation depends on a number
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of factors. The child currently
exhibits developmental delay, but
it is difficult to predict how his
cognitive disability and thrombotic
history will affect him as an adult.
The degree of cognitive disability in
persons with DGS is highly variable.
We do not know whether the patient
will be responsible at some point for
his own care or instead will receive
continuous care from family or
specialists. Without consulting the
parents, the team is not in a good
position to predict the long-term
challenges to the patient’s care.

Scarcity of Donor Organs
Scarcity of pediatric donor organs
is not itself a reason to deny listing
for transplantation in a particular
case. Rather, scarcity is a background
condition of all transplantation cases
against which hospitals and medical
organizations ought to develop
allocation mechanisms that are just.
If there is good evidence that the
transplantation would be futile or
lead to a poor outcome, then these
would be ethically defensible reasons
for withholding transplantation. In
this case, the team did not offer such
evidence to support its decision.

The WGS Findings
Of the 4 reasons provided as
justification for the team’s decision,
the WGS findings seem to be doing
the most work. The first 3 reasons
were presumably weighed when
the patient was initially considered
for heart transplantation (before
WGS), and the team reached the
decision not to move forward with
listing only after the WGS findings
were returned. Why did the genetic
diagnosis lead to this decision?
A diagnosis of DGS does not itself
indicate that heart transplantation
would result in a poor outcome. The
phenotypic presentation of DGS is
extremely variable, and there is a
great deal of clinical uncertainty
with respect to posttransplantation
outcome. Moreover, the team

would have been familiar with the
patient’s phenotypic presentation
when he was initially considered
for transplantation, and the patient
was not determined to be a poor
candidate for transplantation at
that time. The WGS findings show
that the child’s cognitive disability
is likely to become more severe as
he matures and that there is a high
probability that he will develop
adult-onset psychiatric illness.
But these possibilities would not
provide justification for a unilateral
decision to deny transplantation. It
is unclear, then, why the genomic
results so strongly affected the team’s
deliberation.
If, as seems to be the case, the
consent process did not include
disclosure of the potential impact of
WGS on the patient’s management,
then the parents’ objections are
justifiable and appropriate. The
team ought to seek to revisit
treatment options with the parents.
The parents should be involved in
the decision-making about listing
for transplantation and/or using a
ventricular assist device. Initiating
this conversation might go some
way toward reestablishing trust
between the parents and the team.
It also would be an opportunity for
the team to gather more information
about the parents’ already extensive
experience handling the challenges
of postoperative care for their child,
their ability to provide adequate
posttransplantation care, and their
perception of their own abilities to
provide that care. Without discussing
these matters with the parents, the
team is in no place to determine
how prepared the family is for the
psychosocial challenges and complex
care the patient may require.
Reopening this discussion need not
require that the team abandon its
original concerns about listing for
transplantation. But these concerns
should be expressed at the beginning
of the conversation with the parents
about treatment options.

Dr Lantos Comments
This case brings together 3 of the
most controversial issues in pediatric
bioethics today: the allocation of
organs for transplantation, the use of
genome sequencing to predict future
health problems, and the assessment
of quality of life. It is not surprising
to find disagreement among experts.
The allocation of scarce resources
requires robust theories of justice
and political integrity in applying
those theories to the real world of
individual patients and families
who might benefit or be harmed
unjustly. Genomics requires humility
in the face of highly uncertain
and probabilistic findings that we
know, given our current state of
understanding, can only be tentative
and are likely to be inaccurate. The
only way to muddle through this
domain of uncertainties will be by
carefully and humbly presenting
and analyzing cases like this one
to determine when and whether
genomic findings should be part of
the equation of organ allocation. We
welcome reader comments on this
case and presentation of other cases
that raise similar issues.

ABBREVIATIONS
DGS: DiGeorge syndrome
ECMO: extracorporeal membrane
oxygenation
WGS: whole genome sequencing
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